Skip to main content
Wolfson Institute of Population Health
  1. WIPH
  2. People
  3. Profiles

Caitlin Fierheller, PhD

Caitlin

Postdoctoral Research Fellow in Women’s Precision Prevention

Email: c.fierheller@qmul.ac.uk

Profile

I joined the Women’s Precision Prevention (WPP) team with Prof Ranjit Manchanda as a postdoctoral research associate in February 2023. I am currently working across clinical trials in the WPP team which focus on population-based genetic testing, targeted screening, cancer prevention (including surgical) and health economics. I am a co-investigator on the PROTECT-C (Population based germline testing for early detection and prevention of cancer) and DETECT-2 (Direct to patient testing at cancer diagnosis for precision prevention-2). I also work on the Jewish Hereditary Cancer Review, PRESCORES (Preventing Endometrial Cancers: Comparing Risk-Reducing Strategies), PROTECTOR (Prevention ovarian cancer through early excision of tubes and late ovarian removal), and other studies.

I completed my PhD in Human Genetics at McGill University, Montreal, Canada in 2023. My research focused on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer. I obtained my BSc in 2016 in Genetics and Biochemistry from Western University, London, Canada.

Research

Research Interests:

Cancer prevention

Cancer genetics

Population-based genetic testing

Publications

  • Ganesan S, Mansour L, Dibden A et al. (2026). Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis. nameOfConference


  • Sia J, Lane E, Fierheller C et al. (2026). Estimands for clinical effectiveness of risk reducing early salpingectomy in high risk women from prospective observational studies. nameOfConference


    QMRO: qmroHref
  • Sia J, Dibden A, Oxley S et al. (2026). Evaluating the clinical effectiveness and potential impact of opportunistic bilateral salpingectomy in 21.8 million UK general population women. nameOfConference


    QMRO: qmroHref
  • Fierheller CT, Deshmukh P, Kalra A et al. (2026). Protocol for the DETECT-2 randomised controlled trial: a comparison of direct-to-patient versus mainstreaming genetic testing at ovarian, endometrial and colorectal cancer diagnosis. nameOfConference


  • Ganesan S, Mansour L, Dibden A et al. (2026). Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN in 38,337 women: a systematic review and meta-analysis. nameOfConference


    QMRO: qmroHref
  • Fierheller CT, Leung EYL, Alcaraz M-L et al. (2025). Consent model for tumour genetic testing in ovarian cancer. nameOfConference


  • Sideris M, Brincat MR, Blyuss O et al. (publicationYear). P-POSSUM Falls Short: Predicting Morbidity in Ovarian Cancer (OC) Cytoreductive Surgery. nameOfConference


  • Sia J, Lane EF, Fierheller CT et al. (2025). Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer. nameOfConference


  • Wei X, Mansour L, Oxley S et al. (2025). Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention. nameOfConference


  • Kalra A, Ganesan S, Sia JJY et al. (2025). Uptake and patient-related outcomes of mainstreaming genetic testing: a systematic review and meta-analysis. nameOfConference


View profile publication page
Back to top